The major goal of this study is to evaluate the cellular immune response to a cancer vaccine produced by Janssen.

The major goal of this is to assess the ability of Mtb-specific CD4 T cells from ART versus ART + IPT animals to active antimicrobial functions of Mtb-infected macrophages while promoting diversity.

This research project will be undertaken to define the structure-function relationships of the enzymes of riboflavin biosynthesis.Riboflavin biosynthesis includes five enzymatic activities that are unparalleled in nature. This pathway has been studied in sufficient detail to establish the chemical transformations performed by each enzyme and the salient characteristics of the enzymes. The focus of this proposal is the mechanisms of the unusual deformylation reactions of RibA and RibB and the unconventional multi-activity of RibD will be defined.

The central goal of this application is to demonstrate that recombinant forms of the prototypic mammarenavirus lymphocytic choriomeningitis virus (LCMV) containing a codon deoptimized (CD) nucleoprotein (NP) expressing glycoproteins (GP) of HF-causing LASV and JUNV (rLCMV/NPCD/GPHF) can be used for the development of a safe and protective individual or blended live-attenuated vaccine (LAV) to combat HF disease caused by LASV and JUNV infections.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. CIPN is a common clinical problem; approximately 30-40% of patients receiving neurotoxic chemotherapy will suffer from this condition and. unfortunately. there is no preventive treatment for CIPN. Our recent study on neurodegeneration suggests that cell cycle re-entry in peripheral neurons play a critical role in the development of CIPN and targeting neuronal cell cycle machinery may be a highly effective therapy for CIPN. To test this idea.

The major goal of this project is to screen the U42 macaque colony at the SNPRC for SARS-CoV-2 virus and viral antibodies to mitigate the risks to both staff and the nonhuman primate colonies associated with COVID-19 and to help minimize any risk to HIV research using U42 funded Indian-origin rhesus macaques.

Southwest Research Institute (SwRI) and The University of Texas at San Antonio (UTSA) are working to synthesize novel highly potent derivatives of the antimalarial drug artemisinin with the goal of creating a powerful, cost-effective malaria treatment. Led by Dr. Shawn Blumberg of SwRI’s Chemistry and Chemical Engineering Division and Dr. Doug Frantz of the Department of Chemistry within UTSA’s College of Sciences, the work is supported by a $125,000 grant from the Connecting through Research Partnerships (CONNECT) program.

The Particle Science and Technology Laboratory at Southwest Research Institute has expanded its services to include mask testing in response to the COVID-19 pandemic. The testing will help health care and other organizations evaluate respirators, surgical face masks and filtration materials to ensure they meet particle filtration standards.

Fueling transformative research through collaboration, the San Antonio Partnership for Precision Therapeutics (SAPPT) announces the funding of three more collaborative COVID-19 research efforts in San Antonio. SAPPT has awarded more than $600,000 to fund these projects, following the funding of a COVID-19 vaccine project announced in April.